+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Calcium Channel Blocker Drugs Market, by Drug Class, by Disease Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2022
  • Region: Global
  • Coherent Market Insights Pvt Ltd.
  • ID: 5648826
Calcium channel blockers are class of medicines used for the treatment of hypertension, irregular heartbeats called arrhythmias and chest pain related to angina they work by blocking some of the calcium that enters the heart and arteries. Calcium channel blocker drugs are available in many forms which ranging from short-acting dissolving tablets to extended-release capsules. The dosage will depend on overall health and medical history of patients.

Moreover, chronic kidney disease is the progressive loss of kidney function over a period of several years. As kidney failure advances to further stages, and the organ’s function is severely impaired, dangerous levels of waste and fluid can rapidly build up in the body. Treatment is aimed at stopping or slowing down the progression of the disease - this is usually done by controlling its underlying cause calcium channel blockers are drug used in the treatment of chronic kidney disease or its underlying cause.

Market Dynamics

Increasing prevalence of cardiovascular disease, obesity, unhealthy life style is expected to drive the market growth during the forecast period.

For instance, according to the World Health Organization 2022, an estimated 17.9 million people are died from cardiovascular disease in 2019 form which 85% death are occur due to heart attack and stroke worldwide.

Increasing lunches and approval of calcium channel blocker drug is expected to witness significant growth of the market over the forecast period

For instance, in June 2022, CMP Pharma, Inc., a pharmaceutical company receive the U.S. Food and Drug Administration approval for its Norliqva (amlodipine) oral solution, 1 mg/mL, an oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker for the treatment of hypertension in patients 6 years of age and older.

Key features of the study:

  • This report provides an in-depth analysis of the global calcium channel blocker drugs market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global calcium channel blocker drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global calcium channel blocker drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcium channel blocker drugs market

Detailed Segmentation:

Global Calcium Channel Blocker Drugs Market, By Drug Class:

  • Benzothizepine
  • Dihydropyridine
  • Phenylalkylamine

Global Calcium channel blocker drugs market, By Disease Indication:

  • Hypertension
  • Chest Pain
  • Arrhythmias
  • Others (Blood vessel conditions, Coronary Artery Disease etc.)

Global Calcium Channel Blocker Drugs Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Global Calcium Channel Blocker Drugs Market, By Region:

  • North America
  • By Country
  • U.S.
  • Canada
  • Latin America
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Country
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Rest Of Europe
  • Asia Pacific
  • By Country
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Country/Region
  • South Africa
  • Central Africa
  • North Africa

Company Profiles

  • Bausch Health*
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd
  • Lupin
  • Arbor Pharmaceuticals
  • GlaxoSmithKline Plc
  • Biopharma
  • Sofgen Pharmaceuticals
  • Glenmark Pharmaceuticals Inc
  • Amneal Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd,
  • Novartis AG
  • Zydus Cadila
  • Pfizer Inc,
“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations
2. Market Purview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Disease Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
  • Drivers
  • Restraints
  • Opportunities
  • Impact Analysis
  • Key Development Strategies
  • Mergers And Acquisition Scenario
  • Market Trends
  • Brand Analysis
  • Regulatory Scenario
  • PEST Analysis
  • Pricing Analysis
4. Global Calcium Channel Blocker Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
  • COVID-19 Epidemiology
  • Impact on Manufacturing
  • Impact on Manufacturing
5. Global Calcium Channel Blocker Drugs Market, By Drug Class, 2017 - 2030, (US$ Mn)
  • Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017-2030
  • Segment Trends
  • Benzothizepine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Dihydropyridine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Phenylalkylamine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
6. Global Calcium Channel Blocker Drugs Market, By Disease Indication, 2017 - 2030, (US$ Mn)
  • Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017-2030
  • Segment Trends
  • Hypertension
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Chest Pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Arrhythmias
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Others (Blood vessel conditions, Coronary Artery Disease etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
7. Global Calcium Channel Blocker Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017-2030
  • Segment Trends
  • Hospital Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Retail Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Online Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
8. Global Calcium Channel Blocker Drugs Market, By Region, 2017 - 2030, (US$ Mn)
  • Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • North America
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • U.S.
  • Canada
  • Latin America
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Region/Country, 2017 - 2030, (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa
9. Competitive Landscape
  • Competitive Snapshot
  • Bausch Health*
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Mylan N.V.
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Lupin
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Arbor Pharmaceuticals
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • GlaxoSmithKline Plc
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Biopharma
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Sofgen Pharmaceuticals
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Glenmark Pharmaceuticals Inc
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Amneal Pharmaceuticals
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Sun Pharmaceutical Industries Ltd,
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Novartis AG
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Zydus Cadila
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Pfizer Inc,
  • Company Overview
  • Disease Indication Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
10. Section
  • References
  • Research Methodology
  • About us and Sales Contact

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bausch Health
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd
  • Lupin
  • Arbor Pharmaceuticals
  • GlaxoSmithKline Plc
  • Biopharma
  • Sofgen Pharmaceuticals
  • Glenmark Pharmaceuticals Inc
  • Amneal Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd,
  • Novartis AG
  • Zydus Cadila
  • Pfizer Inc,